CARISMA THERAP (CARM)
(Delayed Data from NSDQ)
$1.33 USD
+0.02 (1.53%)
Updated May 31, 2024 04:00 PM ET
After-Market: $1.31 -0.02 (-1.50%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CARM 1.33 +0.02(1.53%)
Will CARM be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for CARM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CARM
Carisma Therapeutics Inc. (CARM) Reports Q1 Loss, Misses Revenue Estimates
Carisma Therapeutics Inc. (CARM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
CARM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why CARISMA THERAP (CARM) Is a Great 'Buy the Bottom' Stock Now
Wall Street Analysts Predict a 48.37% Upside in Carisma Therapeutics Inc. (CARM): Here's What You Should Know
Other News for CARM
Carisma Therapeutics to Participate in the Jefferies Global Healthcare Conference
The Analyst Verdict: CARISMA Therapeutics In The Eyes Of 4 Experts
Buy Rating Affirmed for Carisma Therapeutics Amid Progress in CAR-Monocyte Cancer Therapy
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte
Carisma Therapeutics: First patient dosed in Phase 1 clinical trial of CT-0525